Načítá se...
Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
PURPOSE: To evaluate secondary outcomes including changes in functioning and disability associated with galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, in patients with chronic migraine. METHODS: Patients randomly received galcanezumab (120 mg n = 278, 240 mg n = 27...
Uloženo v:
| Vydáno v: | Qual Life Res |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7847867/ https://ncbi.nlm.nih.gov/pubmed/32930994 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11136-020-02623-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|